Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Cizzle Biotechnology Holdings PLC (CIZ) AI Stock Analysis

3 Followers
GB:CIZ

Cizzle Biotechnology Holdings PLC

(LSE:CIZ)

Select Model
Rating:39Underperform
Price Target:GBX 1.00â–¼(-11.11% Downside)
Action:reiterated
Date:10/16/26

The score is constrained primarily by severe financial weakness, including no revenue, negative equity, and continued cash burn. Weak technical momentum and a negative P/E add further pressure, while near-oversold indicators provide only a limited positive.

Positive Factors
Low reported debtVery low reported debt limits interest obligations and reduces direct leverage risk while the company develops its diagnostic technology. This provides some financial resilience relative to a similarly loss-making business with substantial borrowings, although equity erosion remains a concern.
Negative Factors
No reported revenueThe absence of reported revenue shows that the business has not yet demonstrated commercial adoption or recurring income from its diagnostic technology. Until validation, regulatory progress, and commercialization generate sales, funding requirements remain dependent on activities before a proven revenue base.

Cizzle Biotechnology Holdings PLC (CIZ) vs. iShares MSCI United Kingdom ETF (EWC)

-50%-25%0%25%50%75%100%125%GB:CIZ-33.82%EWC+21.04%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
GBP 5.40M
Dividend Yield
―
Average Volume (3M)
1.90M
Price to Earnings (P/E)
-7.0
Beta (1Y)
-0.98
Revenue Growth
―
EPS Growth
42.86%
Country
UK
Employees
5
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Cizzle Biotechnology Holdings PLC Business Overview & Revenue Model

Company Description

Cizzle Biotechnology Holdings Plc specializes in developing an advanced immunoassay diagnostic test. This innovative tool aims to identify the CIZ1B biomarker, facilitating the early detection of lung cancer. The company, previously known as Cizzle B...

How the Company Makes Money

Cizzle Biotechnology’s primary intended revenue model is to generate income from the commercialization of its lung-cancer diagnostic technology, typically through licensing and/or partnership arrangements with established diagnostics, laboratory, or...

Cizzle Biotechnology Holdings PLC Financial Statement Overview

Summary

Severe pre-revenue risks, persistent losses, negative equity, shrinking assets, and ongoing cash burn outweigh improving loss control and zero debt.

Income Statement

12Very Negative

Balance Sheet

25Negative

Cash Flow

28Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue000000
Gross Profit-1,00000000
EBITDA-724.00K-753.00K20-962.04K-3.96M
Net Income-652.00K-691.00K-2,166-1,717-910.00K-3.92M
Balance Sheet
Total Assets191.00K245.00K492.00K1.69M2.79M1.16M
Cash, Cash Equivalents and Short-Term Investments81.00K116.00K387.00K1.56M478.00K875.00K
Total Debt000000
Total Liabilities528.00K585.00K410.00K186.00K145.00K218.00K
Stockholders Equity-337.00K-340.00K82.00K1.51M2.64M937.00K
Cash Flow
Free Cash Flow-532.00K-498.00K-358.00K-639.00K-872.00K-1.21M
Operating Cash Flow-532.00K-496.00K-358.00K-639.00K-872.00K-1.01M
Investing Cash Flow0-2,00000-120.00K-154.00K
Financing Cash Flow431.00K249.00K579.00K305.00K595.00K2.03M

Cizzle Biotechnology Holdings PLC Technical Analysis

Technical Analysis SentimentNegative
Last Price1.13

Price Trends

50DMA1.33Negative
100DMA1.63Negative
200DMA1.94Negative

Market Momentum

MACD-0.05Negative
RSI34.32Neutral
STOCH28.80Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:CIZ, the sentiment is Negative. The current price of 1.13 is above the 20-day moving average (MA) of 1.11, below the 50-day MA of 1.33, and below the 200-day MA of 1.94, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 34.32 is Neutral, neither overbought nor oversold. The STOCH value of 28.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:CIZ.

Cizzle Biotechnology Holdings PLC Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

GB:CIZ against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
GB:VALGB:VAL46NeutralGBP 2.11M-0.81-71.49%―-34.36%57.45%
GB:TCFGB:TCF42NeutralGBP 4.64M-1.70-93.92%――55.56%
GB:NFXGB:NFX39UnderperformGBP 2.48M-1.93-83.53%――93.02%
GB:CIZGB:CIZ39UnderperformGBP 5.40M-7.03192.61%――42.86%
GB:OPTIGB:OPTI32UnderperformGBP 4.70M-1.10-77.85%―11.90%-2864.29%
GB:FUMGB:FUM31UnderperformGBP 4.15M-0.41-152.41%―-70.77%60.39%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%GB:CIZGB:TCFGB:FUMGB:NFXGB:OPTIGB:VALDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GB:CIZ and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GB:CIZCizzle Biotechnology Holdings PLC1.13-0.52-31.82%
GB:TCFEvgen Pharma0.17-0.04-19.05%
GB:FUMFutura Medical0.26-1.02-79.77%
GB:NFXNuformix Plc0.09-0.19-67.27%
GB:OPTIOptiBiotix Health4.55-3.70-44.85%
GB:VALValiRx plc0.15-0.08-34.04%

Cizzle Biotechnology Holdings PLC Corporate Events

Business Operations and StrategyProduct-Related Announcements

Cizzle Biotechnology Gains Industry Recognition for Early Lung Cancer Test

Positive
Oct 19, 2026

Cizzle Biotechnology Holdings PLC, a UK-based developer of blood-based diagnostics for early cancer detection, is advancing commercialisation of its CIZ1B biomarker test for early-stage lung cancer. The test, built on research into the CIZ1 protein a...

Business Operations and StrategyProduct-Related Announcements

Cizzle Biotechnology Restructures U.S. Royalty Deal as Lung Cancer Test Rollout Accelerates

Positive
Oct 15, 2026

Cizzle Biotechnology has validated its CIZ1B lung cancer biomarker test in a CLIA-accredited U.S. laboratory and is expanding access through additional partners such as BioBridge Global to build a resilient national testing network. The company suppo...

Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingProduct-Related AnnouncementsRegulatory Filings and Compliance

Cizzle Biotechnology Enters Commercial Phase as U.S. Lung Cancer Test Wins CLIA Approval

Positive
Sep 30, 2026

Cizzle Biotechnology has transitioned from development to commercialisation after its CIZ1B biomarker blood test for early-stage lung cancer gained CLIA accreditation for clinical use in the U.S., unlocking access to the world’s largest diagnostics m...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 16, 2026